FIRST-IN-MAN STUDY OF 4SC-202, A NOVEL ORAL HDAC INHIBITOR IN PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES; (TOPAS STUDY)

被引：0
|
作者：
von Tresckow, B. [1 ]
Goebeler, M. E. [2 ]
Sayehli, C. [2 ]
Gundermann, S. [2 ]
Eichenauer, D. [1 ]
Aulitzky, W. [3 ]
Bacchus, L. [3 ]
Igel, S. [4 ]
Schwab, M. [4 ]
Sasse, S. [1 ]
Hauns, B. [5 ]
Mais, A. [5 ]
Hentsch, B. [5 ]
Kohlhof, H. [5 ]
Krauss, R. [5 ]
Krauss, B. [5 ]
Baumgartner, R. [5 ]
Vitt, D. [5 ]
Engert, A. [1 ]
机构：
[1] Univ Hosp Cologne, Cologne, Germany
[2] Univ Hosp Wuerzburg, Wurzburg, Germany
[3] Robert Bosch Krankenhaus, Stuttgart, Germany
[4] Dr Margarte Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany
[5] 4SC AG, Planegg Martinsried, Germany
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1858
引用
收藏
页码：711 / 711
页数：1
相关论文
共 50 条
  • [21] Phase Ib cohort 1 data of class I HDAC inhibitor 4SC-202 in combination with pembrolizumab in advanced cutaneous melanoma patients refractory or non-responding to prior anti-PD1 therapy
    Hamm, Svetlana
    Hermann, Frank
    Bartz, Rene
    JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17
  • [22] Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study
    Hurwitz, Herbert I.
    Smith, David C.
    Pitot, Henry C.
    Brill, Jeffrey M.
    Chugh, Rashmi
    Rouits, Elisabeth
    Rubin, Joseph
    Strickler, John
    Vuagniaux, Gregoire
    Sorensen, J. Mel
    Zanna, Claudio
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (04) : 851 - 859
  • [23] Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study
    Herbert I. Hurwitz
    David C. Smith
    Henry C. Pitot
    Jeffrey M. Brill
    Rashmi Chugh
    Elisabeth Rouits
    Joseph Rubin
    John Strickler
    Gregoire Vuagniaux
    J. Mel Sorensen
    Claudio Zanna
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 851 - 859
  • [24] A first-in-man phase I study of R306465, a histone deacetylase (HDAC) inhibitor exploring pharmacokinetics (PK) and pharmacodynamics (PD) utilizing an electrochemiluminescent immunoassay in patients (p) with advanced tumours
    Fong, P. C.
    Settatree, S.
    Sinha, R.
    Hardcastle, A.
    Hellemans, P. W.
    Arts, J.
    Brown, K. H.
    Janicot, M.
    Aherne, W.
    De Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] A phase I study of the histone deacetylase (HDAC) inhibitor PXD101 in patients with advanced hematological tumors
    Hansen, M
    Gimsing, P
    Rasmussen, A
    Jensen, PB
    Knudsen, LM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 225S - 225S
  • [26] First clinical data of resminostat, a novel oral histone deacetylase (HDAC) inhibitor, in patients with hepatocellular carcinoma (HCC): The SHELTER study
    Bitzer, M.
    Horger, M.
    Ebert, M. P.
    Ganten, T.
    Woerns, M. A.
    Hauns, B.
    Mais, A.
    Jankowsky, R.
    Hentsch, B.
    Lauer, U. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies
    Joleen M. Hubbard
    Jun Yin
    Erin L. Schenk
    Rui Qin
    Joel M. Reid
    Carrie Strand
    Jack Fiskum
    Michael Menefee
    Grace Lin
    L. Austin Doyle
    Percy Ivy
    Charles Erlichman
    Alex Adjei
    Paul Haluska
    Brian A. Costello
    Investigational New Drugs, 2022, 40 : 115 - 123
  • [28] Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies
    Hubbard, Joleen M.
    Yin, Jun
    Schenk, Erin L.
    Qin, Rui
    Reid, Joel M.
    Strand, Carrie
    Fiskum, Jack
    Menefee, Michael
    Lin, Grace
    Doyle, L. Austin
    Ivy, Percy
    Erlichman, Charles
    Adjei, Alex
    Haluska, Paul
    Costello, Brian A.
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (01) : 115 - 123
  • [29] A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors
    Reid, Alison H. M.
    Protheroe, Andrew
    Attard, Gerhardt
    Hayward, Nikki
    Vidal, Laura
    Spicer, James
    Shaw, Heather M.
    Bone, Elizabeth A.
    Carter, Joanne
    Hooftman, Leon
    Harris, Adrian
    De Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2009, 15 (15) : 4978 - 4985
  • [30] A phase I/II study of intravenous LBH589, a novel histone deacetylase (HDAC) inhibitor, in patients (pts) with advanced hematologic malignancies.
    Giles, FJ
    Fischer, T
    Cortes, J
    Beck, J
    Ravandi-Kashani, F
    Garcia-Manero, G
    Kantarjian, HM
    Peng, B
    Rae, PE
    Laird, G
    Sharma, S
    Dugan, M
    Albitar, M
    Bhalla, KM
    BLOOD, 2004, 104 (11) : 499A - 499A
12345